Breton G, Mendoza P, Hgglf T, Oliveira TY, Schaefer-Babajew D, Gaebler C et al
Pre-publication history The pre-publication history for this paper can be accessed here: Acknowledgements Funding for logistical assistance such as publication costs was provided by the Cyclic Vomiting Syndrome Association Additional information Competing interests The author declares that they have no competing interests
Orforglipron treatment also improved several cardiometabolic measures, including waist circumference, systolic blood pressure, and fasting lipid levels
Wegovy underwent years of clinical trials with thousands of participants before approval
Across the dose groups studied (1 mg, 4 mg, 8 mg, and 12 mg weekly subcutaneous doses), nausea rates varied according to the dose administered and the speed of dose escalation